Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dosimetry comparison of 177Lu-rhPSMA-10.1 versus Pluvicto in metastatic prostate cancer
NL-OMON59547Phase 1Completed
- Sponsor
- Blue Earth Therapeutics
- Start
- Feb 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan and lutetium (177Lu) rhPSMA-10.1 in prostate cancer (PCa), sponsored by Blue Earth Therapeutics. Primary endpoint: Tumor-to-kidney absorbed dose ratio comparison. Started Feb 2025; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetanlutetium (177Lu) rhPSMA-10.1
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON59547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59547.